Nuveen
NTLA icon

Nuveen’s Intellia Therapeutics NTLA Stock Holding History

Nuveen’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Buy
377,646
+136,829
+57% +$1.92M ﹤0.01% 1953
2026
Q1 		$3.09M Buy
240,817
+8,085
+3% +$103K ﹤0.01% 2095
2025
Q4 		$2.09M Hold
232,732
– – ﹤0.01% 2274
2025
Q3 		$4.02M Sell
232,732
-4,709
-2% -$58K ﹤0.01% 2008
2025
Q2 		$2.23M Sell
237,441
-34,856
-13% -$286K ﹤0.01% 2254
2025
Q1 		$1.94M Buy
272,297
+11,600
+4% +$117K ﹤0.01% 2348
2024
Q4 		$3.04M Sell
260,697
-105,170
-29% -$1.64M ﹤0.01% 2211
2024
Q3 		$7.52M Sell
365,867
-499,764
-58% -$11.5M ﹤0.01% 1779
2024
Q2 		$19.4M Buy
865,631
+481,763
+126% +$11.5M 0.01% 1154
2024
Q1 		$10.6M Sell
383,868
-91,880
-19% -$2.55M ﹤0.01% 1552
2023
Q4 		$14.5M Sell
475,748
-32,812
-6% -$943K ﹤0.01% 1354
2023
Q3 		$16.1M Buy
508,560
+7,332
+1% +$284K 0.01% 1172
2023
Q2 		$20.4M Sell
501,228
-556,990
-53% -$22.6M 0.01% 1049
2023
Q1 		$39.4M Buy
1,058,218
+394,012
+59% +$15.5M 0.01% 659
2022
Q4 		$23.2M Buy
664,206
+272,982
+70% +$13M 0.01% 938
2022
Q3 		$21.9M Sell
391,224
-32,690
-8% -$2.03M 0.01% 950
2022
Q2 		$21.9M Buy
423,914
+84,420
+25% +$4.29M 0.01% 991
2022
Q1 		$23.8M Sell
339,494
-15,014
-4% -$1.27M 0.01% 1080
2021
Q4 		$41.9M Sell
354,508
-31,272
-8% -$3.92M 0.01% 775
2021
Q3 		$51.8M Sell
385,780
-56,977
-13% -$8.63M 0.02% 670
2021
Q2 		$71.7M Sell
442,757
-111,200
-20% -$8.66M 0.02% 592
2021
Q1 		$44.5M Buy
553,957
+44,722
+9% +$3M 0.01% 789
2020
Q4 		$27.7M Buy
509,235
+50,035
+11% +$1.82M 0.01% 1034
2020
Q3 		$9.13M Buy
459,200
+17,917
+4% +$374K ﹤0.01% 1578
2020
Q2 		$9.28M Buy
441,283
+144,568
+49% +$2.46M ﹤0.01% 1526
2020
Q1 		$3.63M Sell
296,715
-302,688
-50% -$4.08M ﹤0.01% 1888
2019
Q4 		$8.79M Buy
599,403
+451,102
+304% +$6.28M ﹤0.01% 1662
2019
Q3 		$1.98M Buy
148,301
+716
+0.5% +$11.4K ﹤0.01% 2406
2019
Q2 		$2.42M Buy
+147,585
New +$2.32M ﹤0.01% 2345

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Nuveen's NTLA Position: Q2 2026 in Review

Nuveen increased its Intellia Therapeutics (NTLA) stake by 57% in Q2 2026, buying an estimated $1.92M and bringing the position to 377,646 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Nuveen first reported a position in NTLA in Q2 2019 and has held it in 29 quarters since. The position peaked at $71.7M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Nuveen held 377,646 shares of Intellia Therapeutics worth $6.39M as of Q2 2026.
  • Nuveen bought 136,829 Intellia Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Intellia Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1953 holding.
  • Nuveen first reported a position in Intellia Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Intellia Therapeutics position peaked at $71.7M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.